Related Experiment Videos
Adenosine-tri-phosphate treatment for supraventricular tachycardia in infants
D De Wolf1, G Rondia, H Verhaaren
1A.Z.-Kinderen V.U.B., Brussels, Belgium.
Insights
Striadyne, containing adenosine-triphosphate (ATP), effectively terminated supraventricular tachycardia (SVT) in infants under six months. The study highlights ATP
Area of Science:
- Cardiology
- Pediatric Electrophysiology
Background:
- Adenosine is known for its anti-arrhythmic effects on myocardial conduction.
- Renewed interest exists in using adenosine or adenosine-triphosphate (ATP) for supraventricular tachycardia (SVT) termination.
Purpose of the Study:
- To evaluate the efficiency and safety of Striadyne (ATP and other nucleosides) in infants younger than 6 months for SVT treatment.
- To assess the diagnostic value of ATP in pediatric SVT.
Main Methods:
- A study involving 22 infants under 6 months old.
- Administration of Striadyne for SVT termination and diagnosis.
Main Results:
- Striadyne successfully terminated SVT in 17 infants and was diagnostic in 4 others.
- Recurrences of SVT occurred in 10 of the 17 successfully converted infants but were easily managed.
- No serious side-effects were observed.
Conclusions:
- ATP is effective for terminating re-entry types of tachycardia in infants.
- Striadyne demonstrates diagnostic value and a favorable safety profile in this pediatric age group.
Abstract:
Adenosine is an endogenous nucleoside acting on coronary perfusion and myocardial conduction. Although the anti-arrhythmic effects of adenosine have been known for decades, interest in the use of adenosine or adenosine-triphosphate (ATP) (a precursor of adenosine) in termination of supraventricular tachycardia (SVT) has been renewed. We studied the use of striadyne (ATP and a mixture of other nucleosides including adenosine) in 22 infants younger than 6 months in order to evaluate efficiency and safety of the drug in this particular age group. Striadyne stopped SVT in 17 cases and was diagnostic in another 4 cases. Ten out of 17 successfully converted infants showed one or more reinitiations of SVT, which were easily controlled. The results support the efficiency of ATP for the termination of re-entry types of tachycardia, as well as its diagnostic value and its lack of serious side-effects.